{
    "sources": [
        {
            "title": "MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38627702"
        },
        {
            "title": "Venetoclax was associated with total monthly cost savings versus BTKis",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38626793"
        },
        {
            "title": "Spirooxadiazoline-oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38627294"
        },
        {
            "title": "Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38626745"
        },
        {
            "title": "Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38627586"
        }
    ],
    "summary": "The collected data provides significant insights into the research and treatment of leukemia, highlighting advances in diagnostic markers, treatment efficacy, and cost considerations. Key findings include the identification of MNDA as a potential diagnostic marker in B-cell non-Hodgkin lymphomas and its differential expression across lymphoma subtypes. Another study emphasized the economic benefits of venetoclax-based regimens in treating chronic lymphocytic leukemia, offering cost savings compared to BTK inhibitors. Additionally, research on spirooxadiazoline-oxindoles derived from imatinib shows promising antimyeloproliferative effects in K562 cells, indicating potential for new therapeutic developments. The role of circulating plasma cells in prognosis and the effects of autophagy on immunogenicity in AML treatment were also notable insights, suggesting directions for future clinical strategies and research."
}